Insider Selling: David A. Hinkle Unloads 2,000 Shares of Receptos Stock (RCPT)
Receptos (NASDAQ:RCPT) CAO David A. Hinkle unloaded 2,000 shares of the stock on the open market in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $52.80, for a total transaction of $105,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Receptos (NASDAQ:RCPT) traded up 0.70% during mid-day trading on Wednesday, hitting $53.12. 779,272 shares of the company’s stock traded hands. Receptos has a 52 week low of $17.61 and a 52 week high of $55.00. The stock’s 50-day moving average is $43.81 and its 200-day moving average is $39.88. The company’s market cap is $1.449 billion.
Receptos (NASDAQ:RCPT) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by $0.19. The company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.28 million. Analysts expect that Receptos will post $-4.09 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Leerink Swann initiated coverage on shares of Receptos in a research note on Wednesday, August 13th. They set an “outperform” rating and a $60.00 price target on the stock. Separately, analysts at Nomura initiated coverage on shares of Receptos in a research note on Monday, June 30th. They set a “buy” rating and a $63.00 price target on the stock. Finally, analysts at BMO Capital Markets set a $58.00 price target on shares of Receptos in a research note on Tuesday, June 10th. Three research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of $55.00.
Receptos, Inc (NASDAQ:RCPT) is a biopharmaceutical company.
Receive News & Ratings for Receptos Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Receptos Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.